![](jpg/gettyimages-1134798557-150x150.jpg)
immunology
-
Pfizer Expands in Immunology With FDA Approval of New Ulcerative Colitis Drug
Pfizer’s new FDA-approved ulcerative colitis drug Velsipity comes from its $6.7 billion Arena Pharmaceuticals acquisition. The small molecule will compete against blockbuster Bristol Myers Squibb drug Zeposia, which addresses the same target.
-
Artificial Intelligence, BioPharma
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Startup Magnet Biomedicine Attracts $50M to Expand Scope of Molecular Glue Drugs
Magnet Biomedicine builds on decades of molecular glue research from its scientific co-founder, Harvard University Professor Stuart Schreiber. The startup is developing drugs that take these glues beyond the biotech industry’s current focus on targeted protein degradation.
-
Immunology & Inflammation Biotech Apogee Plans IPO to Demo Dosing Edge in Eczema
Apogee Therapeutics is planning an IPO to fund clinical development of biologic drugs that could offer dosing advantages over currently available immunology and inflammation drugs. Its lead program is being prepared for Phase 1 testing in atopic dermatitis, or eczema.
-
Eli Lilly Bets $2.4B on Dice Therapeutics’ Oral Drugs for Psoriasis and More
Eli Lilly’s acquisition of Dice Therapeutics comes eight months after the biotech reported positive data from a Phase 1 study in psoriasis. Dice develops oral small molecule drugs intended to offer alternatives to biologic drugs that are injected or infused.
-
Devices & Diagnostics, BioPharma
California dreamin’: A VC firm’s vision for West Coast-focused biotech investment
Red Tree Venture Capital has closed a $272 million fund focused on investing in West Coast life sciences companies. The firm’s founders say they’re filling a need by providing financial support for innovations emerging from the region’s academic labs.
-
Acelyrin’s $300M haul for novel biologic leads a slate of biotech financings
The biggest biotech financing of the past week belongs to a startup developing an immunology drug that could rival blockbuster products sold by big pharmaceutical companies. Cell therapy, cancer, and rare disease also figured into this week’s startup cash hauls.
-
J&J partners with startup Remix, aiming to treat disease by “tuning” RNA
Several biotech companies are rising to the challenge of developing small molecules to drug RNA. Remix Therapeutics is joining the chase, but its different approach has drawn the interest of Johnson & Johnson, which has inked an R&D alliance spanning cancer and immunology.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Artificial Intelligence, BioPharma
Seizing “magic moment” for machine learning, startup Seismic unveils $101M
Machine learning is core to the drug research of Seismic Therapeutic, a new biotech startup developing novel drugs for immunology indications. CEO Jo Viney said the company’s initial focus is addressing dysregulation of adaptive immunity.
-
Pharma, Artificial Intelligence, BioPharma
Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.
-
Pharma, Artificial Intelligence, BioPharma
Cancer & immunology biotech Odyssey embarks with $218M, Gary Glick at helm
Odyssey Therapeutics is the latest startup formed by serial biotech entrepreneur Gary Glick. Odyssey’s destination is oncology and immunology drugs that address novel disease targets, and the biotech now has $218 million in Series A financing to fuel the journey.
-
Devices & Diagnostics, Pharma, BioPharma
Dice’s IPO roll comes up with $204M for R&D of oral drugs to rival biologics
Dice Therapeutics raised $204 million from its IPO to support development of oral drugs that could compete against biologic drugs that are injected or infused. Also debuting on the public markets were Tyra Biosciences and Procept BioRobotics.
-
Wall Street is lukewarm to Vera’s pivot from gene editing to rare kidney disease
Vera Therapeutics raised $47.9 million from its IPO to continue clinical development of its lead asset, a potential treatment for the kidney disease IgA nephropathy. But the company is joining a crowded field of companies aiming to develop a drug for the rare disorder.
-
Startups, MedCitizens, BioPharma
Serimmune CEO: Leveraging the functional antibody repertoire will transform healthcare
In response to emailed questions, the CEO and CTO talk about the immune intelligence startup’s Human Immunity Map — a growing database of immune interactions that can support the development of multiplex diagnostics, vaccines and therapeutics.